TY - JOUR
T1 - Reversal of Sepsis-Like Features of Neutrophils by Interleukin-1 Blockade in Patients With Systemic-Onset Juvenile Idiopathic Arthritis
AU - ter Haar, Nienke M.
AU - Tak, Tamar
AU - Mokry, Michal
AU - Scholman, Rianne C.
AU - Meerding, Jenny M.
AU - de Jager, Wilco
AU - Verwoerd, Anouk
AU - Foell, Dirk
AU - Vogl, Thomas
AU - Roth, Johannes
AU - Leliefeld, Pieter H.C.
AU - van Loosdregt, Jorg
AU - Koenderman, Leo
AU - Vastert, Sebastiaan J.
AU - de Roock, Sytze
N1 - Funding Information:
We would like to thank staff members at the Utrecht Sequence Facility, UMCU Luminex Core Facility, and UMCU Flow Core Facility for performing the RNA-sequencing and Luminex assays and for helping with the cell sorting.
Funding Information:
Supported by the European Union Seventh Framework Programme (project MIAMI; EC-GA 305266), the Interdisciplinary Center of Clinical Research at the University of Muenster (grant Vo2/ 004/14 to Dr. Vogl and grant Ro2/003/15 to Dr. Roth), the German Research Foundation (grants CRC 1009 B8 and B9 to Drs. Vogl and Roth), the Federal Ministry of Education and Research (project AID-NET grant to Dr. Roth), and the Wilhelmina Children’s Hospital Research Fund (institutional grant to Drs. Vastert and de Roock).
Publisher Copyright:
© 2018, American College of Rheumatology
PY - 2018/6
Y1 - 2018/6
N2 - Objective: Neutrophils are the most abundant innate immune cells in the blood, but little is known about their role in (acquired) chronic autoinflammatory diseases. This study was undertaken to investigate the role of neutrophils in systemic-onset juvenile idiopathic arthritis (JIA), a prototypical multifactorial autoinflammatory disease that is characterized by arthritis and severe systemic inflammation. Methods: Fifty patients with systemic-onset JIA who were receiving treatment with recombinant interleukin-1 receptor antagonist (rIL-1Ra; anakinra) were analyzed at disease onset and during remission. RNA sequencing was performed on fluorescence-activated cell-sorted neutrophils from 3 patients with active systemic-onset JIA and 3 healthy controls. Expression of activation markers, apoptosis, production of reactive oxygen species (ROS), and degranulation of secretory vesicles from neutrophils were assessed by flow cytometry in serum samples from 17 patients with systemic-onset JIA and 15 healthy controls. Results: Neutrophil counts were markedly increased at disease onset, and this correlated with the levels of inflammatory mediators. The neutrophil counts normalized within days after the initiation of rIL-1Ra therapy. RNA-sequencing analysis revealed a substantial up-regulation of inflammatory processes in neutrophils from patients with active systemic-onset JIA, significantly overlapping with the transcriptome of sepsis. Correspondingly, neutrophils from patients with active systemic-onset JIA displayed a primed phenotype that was characterized by increased ROS production, CD62L shedding, and secretory vesicle degranulation, which was reversed by rIL-1Ra treatment in patients who had achieved clinical remission. Patients with a short disease duration had high neutrophil counts, more immature neutrophils, and a complete response to rIL-1Ra, whereas patients with symptoms for >1 month had normal neutrophil counts and an unsatisfactory response to rIL-1Ra. In vitro, rIL-1Ra antagonized the priming effect of IL-1β on neutrophils from healthy subjects. Conclusion: These results strongly support the notion that neutrophils play an important role in systemic-onset JIA, especially in the early inflammatory phase of the disease. The findings also demonstrate that neutrophil numbers and the inflammatory activity of systemic-onset JIA are both susceptible to IL-1 blockade.
AB - Objective: Neutrophils are the most abundant innate immune cells in the blood, but little is known about their role in (acquired) chronic autoinflammatory diseases. This study was undertaken to investigate the role of neutrophils in systemic-onset juvenile idiopathic arthritis (JIA), a prototypical multifactorial autoinflammatory disease that is characterized by arthritis and severe systemic inflammation. Methods: Fifty patients with systemic-onset JIA who were receiving treatment with recombinant interleukin-1 receptor antagonist (rIL-1Ra; anakinra) were analyzed at disease onset and during remission. RNA sequencing was performed on fluorescence-activated cell-sorted neutrophils from 3 patients with active systemic-onset JIA and 3 healthy controls. Expression of activation markers, apoptosis, production of reactive oxygen species (ROS), and degranulation of secretory vesicles from neutrophils were assessed by flow cytometry in serum samples from 17 patients with systemic-onset JIA and 15 healthy controls. Results: Neutrophil counts were markedly increased at disease onset, and this correlated with the levels of inflammatory mediators. The neutrophil counts normalized within days after the initiation of rIL-1Ra therapy. RNA-sequencing analysis revealed a substantial up-regulation of inflammatory processes in neutrophils from patients with active systemic-onset JIA, significantly overlapping with the transcriptome of sepsis. Correspondingly, neutrophils from patients with active systemic-onset JIA displayed a primed phenotype that was characterized by increased ROS production, CD62L shedding, and secretory vesicle degranulation, which was reversed by rIL-1Ra treatment in patients who had achieved clinical remission. Patients with a short disease duration had high neutrophil counts, more immature neutrophils, and a complete response to rIL-1Ra, whereas patients with symptoms for >1 month had normal neutrophil counts and an unsatisfactory response to rIL-1Ra. In vitro, rIL-1Ra antagonized the priming effect of IL-1β on neutrophils from healthy subjects. Conclusion: These results strongly support the notion that neutrophils play an important role in systemic-onset JIA, especially in the early inflammatory phase of the disease. The findings also demonstrate that neutrophil numbers and the inflammatory activity of systemic-onset JIA are both susceptible to IL-1 blockade.
UR - http://www.scopus.com/inward/record.url?scp=85046479344&partnerID=8YFLogxK
U2 - 10.1002/art.40442
DO - 10.1002/art.40442
M3 - Article
AN - SCOPUS:85046479344
SN - 2326-5191
VL - 70
SP - 943
EP - 956
JO - Arthritis and Rheumatology
JF - Arthritis and Rheumatology
IS - 6
ER -